Innate Pharma releases its 2025 financial calendar
Innate Pharma announces publication in Science Immunology highlighting innovative next-generation ANKET® IPH6501
Innate Pharma reports Third Quarter 2024 Business Update and Financial Results
Innate Pharma highlights data from its innovative oncology portfolio selected for the SITC Annual Meeting 2024
Innate Pharma announces conference call and webcast for third quarter 2024 results and business updates
Innate Pharma announces its participation in upcoming investor conferences
Innate Pharma appoints Jonathan Dickinson as new Chief Executive Officer and Chairman of the Executive Board
Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024
Innate Pharma announces FDA clearance of the IND for IPH4502, a Nectin-4 ADC to be developed in solid tumors
Innate Pharma reports First Half 2024 Business Update and Financial Results
